Bayer's rising prostate cancer star Nubeqa crosses blockbuster barrier as Xarelto continues downward descent
Fierce Pharma
NOVEMBER 12, 2024
Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns” in the road ahead, Bayer is confident that the course it’s laid out th | As Xarelto generics continue to eat away at sales, Bayer's Nubeqa and Kerendia are picking up the slack while Regeneron-partnered Eylea makes for a solid base.
Let's personalize your content